Overview of Myeloproliferative Neoplasms
Authors:
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 35 (2) , 159-176
Abstract
No abstract availableKeywords
Funding Information
- Icahn School of Medicine at Mount Sinai
This publication has 110 references indexed in Scilit:
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyLeukemia, 2013
- Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohortBlood, 2012
- Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) geneHaematologica, 2011
- Cardiopulmonary function in two human disorders of the hypoxia‐inducible factor (HIF) pathway: von Hippel‐Lindau disease and HIF‐2α gain‐of‐function mutationThe FASEB Journal, 2011
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3Haematologica, 2010
- Advances in understanding the pathogenesis of primary familial and congenital polycythaemiaBritish Journal of Haematology, 2010
- Autoimmunity and the risk of myeloproliferative neoplasmsHaematologica, 2010
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instabilityCarcinogenesis, 2009
- The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndromeBlood, 2009
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005